Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer
Programmed cell death-ligand 1 (PD-L1) on tumor cells can be degraded to soluble form (sPD-L1) and enter circulation, however, the clinical significances of sPD-L1 in peripheral blood remains to be elucidated in non-small-cell lung cancer (NSCLC). We monitored plasma sPD-L1 levels during perioperati...
Gespeichert in:
| Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2023-11, Vol.72 (11), p.3755-3764 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3764 |
|---|---|
| container_issue | 11 |
| container_start_page | 3755 |
| container_title | Cancer Immunology, Immunotherapy |
| container_volume | 72 |
| creator | Teramoto, Koji Igarashi, Tomoyuki Kataoka, Yoko Ishida, Mitsuaki Hanaoka, Jun Sumimoto, Hidetoshi Daigo, Yataro |
| description | Programmed cell death-ligand 1 (PD-L1) on tumor cells can be degraded to soluble form (sPD-L1) and enter circulation, however, the clinical significances of sPD-L1 in peripheral blood remains to be elucidated in non-small-cell lung cancer (NSCLC). We monitored plasma sPD-L1 levels during perioperative periods and evaluated PD-L1-positive cells in tumor tissues in patients with operable NSCLC. Then the correlation between preoperative plasma sPD-L1 levels and relapse-free survival (RFS) was analyzed retrospectively. In patients who underwent radical surgery (
n
= 61), plasma sPD-L1 levels (median; 63.5 pg/mL) significantly increased 1 month after surgery (72.2 pg/mL,
P
|
| doi_str_mv | 10.1007/s00262-023-03527-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10576714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2858990081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-782a32d3dcde532e809f2ab02eeafe65ffb6c634b89a5cb0466a142821df647e3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS1ERZeFL8DJEhcuhrGd2MkJoZZ_0krtoT1bjjNOs0rsxU4q7bfHy1YgOHCa0fj3njzzCHnD4T0H0B8ygFCCgZAMZC00Oz4jG17JMmpq_pxsQFbANEB1SV7mvC-NgLZ9QS6lVpVqhNqQ_W2KQ4h5GR0d54N1C42e5jit3YT09prtOO0xjY_YU5_iTJd1jonZnKMb7VKms3UpHh7sgJmOgYYYWJ7tNDGH00SnNQzU2eAwvSIX3k4ZXz_VLbn_8vnu6hvb3Xz9fvVpx1zVqoXpRlgpetm7HmspsIHWC9uBQLQeVe19p5ySVde0tnYdVEpZXolG8N6rSqPcko9n38Pazdg7DEuykzmkcbbpaKIdzd8vYXwwQ3w0HGqtdDnglrx7ckjxx4p5MfOYT-vYgHHNRjR107YADS_o23_QfVxTKPsVSuuSC4eToThT5VQ5J_S_f8PBnLI05yxNydL8ytIci0ieRbnAYcD0x_o_qp-f-6Jj</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2877035104</pqid></control><display><type>article</type><title>Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer</title><source>SpringerNature Journals</source><source>PubMed Central</source><creator>Teramoto, Koji ; Igarashi, Tomoyuki ; Kataoka, Yoko ; Ishida, Mitsuaki ; Hanaoka, Jun ; Sumimoto, Hidetoshi ; Daigo, Yataro</creator><creatorcontrib>Teramoto, Koji ; Igarashi, Tomoyuki ; Kataoka, Yoko ; Ishida, Mitsuaki ; Hanaoka, Jun ; Sumimoto, Hidetoshi ; Daigo, Yataro</creatorcontrib><description>Programmed cell death-ligand 1 (PD-L1) on tumor cells can be degraded to soluble form (sPD-L1) and enter circulation, however, the clinical significances of sPD-L1 in peripheral blood remains to be elucidated in non-small-cell lung cancer (NSCLC). We monitored plasma sPD-L1 levels during perioperative periods and evaluated PD-L1-positive cells in tumor tissues in patients with operable NSCLC. Then the correlation between preoperative plasma sPD-L1 levels and relapse-free survival (RFS) was analyzed retrospectively. In patients who underwent radical surgery (
n
= 61), plasma sPD-L1 levels (median; 63.5 pg/mL) significantly increased 1 month after surgery (72.2 pg/mL,
P
< 0.001). The combined score of PD-L1-positive cells including tumor cells and tumor-associated macrophages (TAMs) was significantly associated with preoperative plasma sPD-L1 levels. In patients with high levels of preoperative plasma sPD-L1, the probability of 5-year RFS was significantly poor for patients with low PD-L1 expression intensity of tumor cells (tcPD-L1) compared with those with high tcPD-L1 (33.3%
vs.
87.5%, respectively,
P
= 0.016; 95% CI, 0.013–0.964). In former group, PD-L1-positive TAMs were markedly infiltrating compared with those from latter group (246.4
vs.
76.6 counts/mm
2
, respectively,
P
= 0.003). In NSCLC, plasma sPD-L1 can reflect the accumulation of PD-L1-posotive TAMs, not just PD-L1-positive tumor cells. In patients with high levels of preoperative plasma sPD-L1, the prognoses after surgery depends on which PD-L1-positive cells, tumor cells or TAMs, are the primary source of the sPD-L1. Thus, measuring both plasma sPD-L1 levels and PD-L1 expression status of tumor cells and TAMs is of benefit for assessment of postoperative prognosis in operable NSCLC.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-023-03527-y</identifier><identifier>PMID: 37646826</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Apoptosis ; Cancer Research ; Cell death ; Immunology ; Lung cancer ; Macrophages ; Medical prognosis ; Medicine ; Medicine & Public Health ; Non-small cell lung carcinoma ; Oncology ; Patients ; PD-L1 protein ; Peripheral blood ; Plasma ; Prognosis ; Small cell lung carcinoma ; Surgery ; Tumor cells ; Tumors</subject><ispartof>Cancer Immunology, Immunotherapy, 2023-11, Vol.72 (11), p.3755-3764</ispartof><rights>The Author(s) 2023</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-782a32d3dcde532e809f2ab02eeafe65ffb6c634b89a5cb0466a142821df647e3</citedby><cites>FETCH-LOGICAL-c496t-782a32d3dcde532e809f2ab02eeafe65ffb6c634b89a5cb0466a142821df647e3</cites><orcidid>0000-0002-9585-4118 ; 0000-0002-8375-2691 ; 0000-0002-5272-556X ; 0000-0001-6268-6587</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576714/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576714/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,41488,42557,51319,53791,53793</link.rule.ids></links><search><creatorcontrib>Teramoto, Koji</creatorcontrib><creatorcontrib>Igarashi, Tomoyuki</creatorcontrib><creatorcontrib>Kataoka, Yoko</creatorcontrib><creatorcontrib>Ishida, Mitsuaki</creatorcontrib><creatorcontrib>Hanaoka, Jun</creatorcontrib><creatorcontrib>Sumimoto, Hidetoshi</creatorcontrib><creatorcontrib>Daigo, Yataro</creatorcontrib><title>Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><description>Programmed cell death-ligand 1 (PD-L1) on tumor cells can be degraded to soluble form (sPD-L1) and enter circulation, however, the clinical significances of sPD-L1 in peripheral blood remains to be elucidated in non-small-cell lung cancer (NSCLC). We monitored plasma sPD-L1 levels during perioperative periods and evaluated PD-L1-positive cells in tumor tissues in patients with operable NSCLC. Then the correlation between preoperative plasma sPD-L1 levels and relapse-free survival (RFS) was analyzed retrospectively. In patients who underwent radical surgery (
n
= 61), plasma sPD-L1 levels (median; 63.5 pg/mL) significantly increased 1 month after surgery (72.2 pg/mL,
P
< 0.001). The combined score of PD-L1-positive cells including tumor cells and tumor-associated macrophages (TAMs) was significantly associated with preoperative plasma sPD-L1 levels. In patients with high levels of preoperative plasma sPD-L1, the probability of 5-year RFS was significantly poor for patients with low PD-L1 expression intensity of tumor cells (tcPD-L1) compared with those with high tcPD-L1 (33.3%
vs.
87.5%, respectively,
P
= 0.016; 95% CI, 0.013–0.964). In former group, PD-L1-positive TAMs were markedly infiltrating compared with those from latter group (246.4
vs.
76.6 counts/mm
2
, respectively,
P
= 0.003). In NSCLC, plasma sPD-L1 can reflect the accumulation of PD-L1-posotive TAMs, not just PD-L1-positive tumor cells. In patients with high levels of preoperative plasma sPD-L1, the prognoses after surgery depends on which PD-L1-positive cells, tumor cells or TAMs, are the primary source of the sPD-L1. Thus, measuring both plasma sPD-L1 levels and PD-L1 expression status of tumor cells and TAMs is of benefit for assessment of postoperative prognosis in operable NSCLC.</description><subject>Apoptosis</subject><subject>Cancer Research</subject><subject>Cell death</subject><subject>Immunology</subject><subject>Lung cancer</subject><subject>Macrophages</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Patients</subject><subject>PD-L1 protein</subject><subject>Peripheral blood</subject><subject>Plasma</subject><subject>Prognosis</subject><subject>Small cell lung carcinoma</subject><subject>Surgery</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU9v1DAQxS1ERZeFL8DJEhcuhrGd2MkJoZZ_0krtoT1bjjNOs0rsxU4q7bfHy1YgOHCa0fj3njzzCHnD4T0H0B8ygFCCgZAMZC00Oz4jG17JMmpq_pxsQFbANEB1SV7mvC-NgLZ9QS6lVpVqhNqQ_W2KQ4h5GR0d54N1C42e5jit3YT09prtOO0xjY_YU5_iTJd1jonZnKMb7VKms3UpHh7sgJmOgYYYWJ7tNDGH00SnNQzU2eAwvSIX3k4ZXz_VLbn_8vnu6hvb3Xz9fvVpx1zVqoXpRlgpetm7HmspsIHWC9uBQLQeVe19p5ySVde0tnYdVEpZXolG8N6rSqPcko9n38Pazdg7DEuykzmkcbbpaKIdzd8vYXwwQ3w0HGqtdDnglrx7ckjxx4p5MfOYT-vYgHHNRjR107YADS_o23_QfVxTKPsVSuuSC4eToThT5VQ5J_S_f8PBnLI05yxNydL8ytIci0ieRbnAYcD0x_o_qp-f-6Jj</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Teramoto, Koji</creator><creator>Igarashi, Tomoyuki</creator><creator>Kataoka, Yoko</creator><creator>Ishida, Mitsuaki</creator><creator>Hanaoka, Jun</creator><creator>Sumimoto, Hidetoshi</creator><creator>Daigo, Yataro</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9585-4118</orcidid><orcidid>https://orcid.org/0000-0002-8375-2691</orcidid><orcidid>https://orcid.org/0000-0002-5272-556X</orcidid><orcidid>https://orcid.org/0000-0001-6268-6587</orcidid></search><sort><creationdate>20231101</creationdate><title>Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer</title><author>Teramoto, Koji ; Igarashi, Tomoyuki ; Kataoka, Yoko ; Ishida, Mitsuaki ; Hanaoka, Jun ; Sumimoto, Hidetoshi ; Daigo, Yataro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-782a32d3dcde532e809f2ab02eeafe65ffb6c634b89a5cb0466a142821df647e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Apoptosis</topic><topic>Cancer Research</topic><topic>Cell death</topic><topic>Immunology</topic><topic>Lung cancer</topic><topic>Macrophages</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Patients</topic><topic>PD-L1 protein</topic><topic>Peripheral blood</topic><topic>Plasma</topic><topic>Prognosis</topic><topic>Small cell lung carcinoma</topic><topic>Surgery</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Teramoto, Koji</creatorcontrib><creatorcontrib>Igarashi, Tomoyuki</creatorcontrib><creatorcontrib>Kataoka, Yoko</creatorcontrib><creatorcontrib>Ishida, Mitsuaki</creatorcontrib><creatorcontrib>Hanaoka, Jun</creatorcontrib><creatorcontrib>Sumimoto, Hidetoshi</creatorcontrib><creatorcontrib>Daigo, Yataro</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Teramoto, Koji</au><au>Igarashi, Tomoyuki</au><au>Kataoka, Yoko</au><au>Ishida, Mitsuaki</au><au>Hanaoka, Jun</au><au>Sumimoto, Hidetoshi</au><au>Daigo, Yataro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><date>2023-11-01</date><risdate>2023</risdate><volume>72</volume><issue>11</issue><spage>3755</spage><epage>3764</epage><pages>3755-3764</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>Programmed cell death-ligand 1 (PD-L1) on tumor cells can be degraded to soluble form (sPD-L1) and enter circulation, however, the clinical significances of sPD-L1 in peripheral blood remains to be elucidated in non-small-cell lung cancer (NSCLC). We monitored plasma sPD-L1 levels during perioperative periods and evaluated PD-L1-positive cells in tumor tissues in patients with operable NSCLC. Then the correlation between preoperative plasma sPD-L1 levels and relapse-free survival (RFS) was analyzed retrospectively. In patients who underwent radical surgery (
n
= 61), plasma sPD-L1 levels (median; 63.5 pg/mL) significantly increased 1 month after surgery (72.2 pg/mL,
P
< 0.001). The combined score of PD-L1-positive cells including tumor cells and tumor-associated macrophages (TAMs) was significantly associated with preoperative plasma sPD-L1 levels. In patients with high levels of preoperative plasma sPD-L1, the probability of 5-year RFS was significantly poor for patients with low PD-L1 expression intensity of tumor cells (tcPD-L1) compared with those with high tcPD-L1 (33.3%
vs.
87.5%, respectively,
P
= 0.016; 95% CI, 0.013–0.964). In former group, PD-L1-positive TAMs were markedly infiltrating compared with those from latter group (246.4
vs.
76.6 counts/mm
2
, respectively,
P
= 0.003). In NSCLC, plasma sPD-L1 can reflect the accumulation of PD-L1-posotive TAMs, not just PD-L1-positive tumor cells. In patients with high levels of preoperative plasma sPD-L1, the prognoses after surgery depends on which PD-L1-positive cells, tumor cells or TAMs, are the primary source of the sPD-L1. Thus, measuring both plasma sPD-L1 levels and PD-L1 expression status of tumor cells and TAMs is of benefit for assessment of postoperative prognosis in operable NSCLC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37646826</pmid><doi>10.1007/s00262-023-03527-y</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-9585-4118</orcidid><orcidid>https://orcid.org/0000-0002-8375-2691</orcidid><orcidid>https://orcid.org/0000-0002-5272-556X</orcidid><orcidid>https://orcid.org/0000-0001-6268-6587</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer Immunology, Immunotherapy, 2023-11, Vol.72 (11), p.3755-3764 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10576714 |
| source | SpringerNature Journals; PubMed Central |
| subjects | Apoptosis Cancer Research Cell death Immunology Lung cancer Macrophages Medical prognosis Medicine Medicine & Public Health Non-small cell lung carcinoma Oncology Patients PD-L1 protein Peripheral blood Plasma Prognosis Small cell lung carcinoma Surgery Tumor cells Tumors |
| title | Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A27%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20impact%20of%20soluble%20PD-L1%20derived%20from%20tumor-associated%20macrophages%20in%20non-small-cell%20lung%20cancer&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Teramoto,%20Koji&rft.date=2023-11-01&rft.volume=72&rft.issue=11&rft.spage=3755&rft.epage=3764&rft.pages=3755-3764&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-023-03527-y&rft_dat=%3Cproquest_pubme%3E2858990081%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2877035104&rft_id=info:pmid/37646826&rfr_iscdi=true |